$164 Million is the total value of Aisling Capital LLC's 6 reported holdings in Q4 2013. The portfolio turnover from Q3 2013 to Q4 2013 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Q | New | Quintiles Transnational Corp. | $84,500,000 | – | 1,823,575 | +100.0% | 51.65% | – |
| DRTX | New | Durata Therapeutics, Inc. | $40,000,000 | – | 3,130,824 | +100.0% | 24.45% | – |
| CMRX | New | Chimerix, Inc. | $18,500,000 | – | 1,222,943 | +100.0% | 11.31% | – |
| ICPT | New | Intercept Pharmaceuticals | $9,400,000 | – | 137,519 | +100.0% | 5.75% | – |
| New | MEI Pharma, Inc. | $6,200,000 | – | 770,000 | +100.0% | 3.79% | – | |
| SRNE | New | Sorrento Therapeutics, Inc | $5,000,000 | – | 620,700 | +100.0% | 3.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TRANSENTERIX INC. | 22 | Q3 2019 | 12.1% |
| CHIMERIX INC. | 21 | Q4 2018 | 19.4% |
| ADMA BIOLOGICS INC. | 20 | Q3 2019 | 35.5% |
| LOXO ONCOLOGY INC. | 18 | Q4 2018 | 80.9% |
| AIMMUNE THERAPEUTICS INC. | 17 | Q3 2019 | 68.7% |
| CIDARA THERAPEUTICS INC. | 17 | Q3 2019 | 4.1% |
| AGILE THERAPEUTICS INC. | 16 | Q1 2018 | 5.5% |
| ZELTIQ AESTHETICS INC | 14 | Q3 2017 | 16.3% |
| ESPERION THERAPEUTICS INC NE | 14 | Q3 2017 | 24.9% |
| VERSARTIS INC | 13 | Q2 2017 | 16.2% |
View Aisling Capital LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-13 |
| 13F-HR | 2019-08-08 |
| 13F-HR | 2019-05-07 |
| 13F-HR | 2019-02-11 |
| 13F-HR | 2018-11-05 |
| 13F-HR | 2018-08-13 |
| 13F-HR | 2018-05-14 |
| 13F-HR | 2018-02-07 |
| 13F-HR | 2017-11-09 |
| 13F-HR | 2017-08-14 |
View Aisling Capital LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.